Acceleron Pharma Inc XLRN
We take great care to ensure that the data presented and summarized in this overview for ACCELERON PHARMA INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in XLRN
Top Purchases
Top Sells
About XLRN
Insider Transactions at XLRN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 19
2021
|
Habib J Dable CEO and President |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
98,450
-100.0%
|
-
|
|
Nov 19
2021
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
10,681
-100.0%
|
-
|
|
Nov 19
2021
|
Jay T. Backstrom EVP, Research and Development |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
21,233
-100.0%
|
-
|
|
Nov 19
2021
|
Sujay Kango EVP, Chief Commercial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
18,509
-100.0%
|
-
|
|
Nov 19
2021
|
Adam M Veness SVP, General Counsel and Sec. |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
23,423
-100.0%
|
-
|
|
Nov 19
2021
|
Francois Nader Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
6,749
-100.0%
|
-
|
|
Nov 19
2021
|
Laura Hamill Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
474
-100.0%
|
-
|
|
Nov 19
2021
|
Terrence C Kearney Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
6,749
-100.0%
|
-
|
|
Nov 19
2021
|
Thomas A Mccourt Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
6,044
-100.0%
|
-
|
|
Nov 19
2021
|
Karen L. Smith Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,622
-100.0%
|
-
|
|
Nov 19
2021
|
Christopher Hite Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
930
-100.0%
|
-
|
|
Nov 19
2021
|
Kemal Malik Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,622
-100.0%
|
-
|
|
Nov 19
2021
|
Joseph S Zakrzewski Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
34,499
-100.0%
|
-
|
|
Nov 09
2021
|
Adam M Veness SVP, General Counsel and Sec. |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+16.12%
|
$130,500
$29.37 P/Share
|
|
Sep 27
2021
|
Sujay Kango EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-21.27%
|
$875,000
$175.0 P/Share
|
|
Sep 27
2021
|
Sujay Kango EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+17.54%
|
$200,000
$40.61 P/Share
|
|
Sep 24
2021
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
5,370
-33.46%
|
$859,200
$160.38 P/Share
|
|
Sep 24
2021
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,370
+12.86%
|
$220,170
$41.13 P/Share
|
|
Sep 23
2021
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
19,630
-34.97%
|
$3,140,800
$160.76 P/Share
|
|
Sep 23
2021
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,630
+21.77%
|
$726,310
$37.47 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders